Loading...
Xenon Pharmaceuticals Inc.
XENE•NASDAQ
Healthcare
Biotechnology
$30.30
$-0.71(-2.29%)
Xenon Pharmaceuticals Inc. (XENE) Financial Performance & Income Statement Overview
Review Xenon Pharmaceuticals Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-30.48%
↓ 30.48%
Net Income Growth
-28.48%
↓ 28.48%
Operating Cash Flow Growth
-24.81%
↓ 24.81%
Operating Margin
-3906.60%
↓ 3906.60%
Gross Margin
-8.79%
↓ 8.79%
Net Profit Margin
-3352.61%
↓ 3352.61%
ROE
-32.44%
↓ 32.44%
ROIC
-39.88%
↓ 39.88%
Xenon Pharmaceuticals Inc. (XENE) Income Statement & Financial Overview
Review Xenon Pharmaceuticals Inc.'s (XENE) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $659000.00 | $599000.00 |
| Gross Profit | $0.00 | $0.00 | -$659000.00 | -$599000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $58.84M | $56.97M | $49.70M | $44.25M |
| SG&A Expenses | $18.005M | $16.71M | $19.40M | $14.19M |
| Operating Expenses | $77.48M | $73.68M | $69.10M | $58.44M |
| Total Costs & Expenses | $77.48M | $73.68M | $69.10M | $59.04M |
| Interest Income | $9.42M | $10.33M | $10.84M | $11.36M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $633000.00 | $669000.00 | $659000.00 | $599000.00 |
| EBITDA | -$76.84M | -$73.007M | -$68.44M | -$58.44M |
| EBITDA Ratio | ||||
| Operating Income | -$77.48M | -$73.68M | -$69.10M | -$59.04M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $7.94M | $10.57M | $10.85M | $11.52M |
| Income Before Tax | -$69.53M | -$63.11M | -$58.26M | -$47.52M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | -$3.85M | -$320000.00 | -$333000.00 | $412000.00 |
| Net Income | -$65.69M | -$62.79M | -$57.92M | -$47.93M |
| Net Income Ratio | ||||
| EPS | -$0.84 | -$0.81 | -$0.75 | -$0.62 |
| Diluted EPS | -$0.84 | -$0.81 | -$0.75 | -$0.62 |
| Weighted Avg Shares Outstanding | $78.39M | $77.93M | $77.67M | $77.59M |
| Weighted Avg Shares Outstanding (Diluted) | $78.39M | $77.93M | $77.67M | $77.59M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan